SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes. Currently there are no validated noninvasive diagnostics that can diff...

Full description

Bibliographic Details
Main Authors:	Yi Luo, Samir Wadhawan, Alex Greenfield, Benjamin E. Decato, Abdul M. Oseini, Rebecca Collen, Diane E. Shevell, John Thompson, Gabor Jarai, Edgar D. Charles, Arun J. Sanyal
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2021-05-01
Series:	Hepatology Communications
Online Access:	https://doi.org/10.1002/hep4.1670

Similar Items

Assessment of variability in the plasma 7k SomaScan proteomics assay
by: Julián Candia, et al.
Published: (2022-10-01)

SOMAscan Proteomics Identifies Novel Plasma Proteins in Amyotrophic Lateral Sclerosis Patients
by: Elena Berrone, et al.
Published: (2023-01-01)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
by: Shi, L, et al.
Published: (2019)

Proteome-Wide Analysis Using SOMAscan Identifies and Validates Epidermal Growth Factor as a Disease Marker of Collagenous Gastritis
by: Debora Curci, et al.
Published: (2022-01-01)

Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH
by: Davide Povero, et al.
Published: (2020-09-01)

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
by: Elizabeth A. Brown, et al.
Published: (2023-04-01)

Toward a rapid and accurate point-of-care test for active pulmonary tuberculosis: Multiplexed proteomic assay (SOMAscan™) of human serum for microbial and host markers
by: M.A. De Groote, et al.
Published: (2014-04-01)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
by: Weiguo Fan, et al.
Published: (2021-04-01)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
by: James Twiss, et al.
Published: (2023-07-01)

CD4+ T cell activation and inflammation in NASH-related fibrosis
by: Yunfeng Zhou, et al.
Published: (2022-08-01)

Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis
by: Xinlei Li, et al.
Published: (2023-08-01)

The plasma degradome reflects later development of NASH fibrosis after liver transplant
by: Jiang Li, et al.
Published: (2023-06-01)

NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling
by: Yoshiaki Sunami
Published: (2020-09-01)

Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death
by: Reda Albadawy, et al.
Published: (2022-09-01)

Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
by: Sumit Kar, et al.
Published: (2019-01-01)

DNA methylation of SMPD3-based diagnostic biomarkers of NASH and mild fibrosis
by: Na Wu, et al.
Published: (2024-01-01)

A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis
by: Xuecheng Li, et al.
Published: (2023-01-01)

A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH
by: Lyndsey F. Meyer, et al.
Published: (2023-05-01)

A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
by: Xuecheng Li, et al.
Published: (2023-01-01)

Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets?
by: Alexandra Zisser, et al.
Published: (2021-03-01)

The Role of the Histone Methyltransferase EZH2 in Liver Inflammation and Fibrosis in STAM NASH Mice
by: Seul Lee, et al.
Published: (2020-05-01)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
by: J.T. Stefano, et al.
Published: (2015-02-01)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
by: Utibe-Abasi S. Udoh, et al.
Published: (2022-07-01)

PRO‐C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD
by: Catherine C. Cohen, et al.
Published: (2021-11-01)

Nashe and satire
by: Stern, T
Published: (2017)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
by: Jérôme Eeckhoute
Published: (2022-08-01)

Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3
by: Kristy St. Rose, et al.
Published: (2022-10-01)

Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH
by: Xiaoxiao Wang, et al.
Published: (2023-02-01)

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
by: Marie O’Farrell, et al.
Published: (2022-09-01)

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
by: Momoko Hayashi, et al.
Published: (2023-01-01)

The Use of Proteomics in Diagnostics: Liver Fibrosis Biomarkers
by: Gangadharan, B, et al.
Published: (2016)

The Use of Proteomics in Diagnostics: Liver Fibrosis Biomarkers
by: Gangadharan, B, et al.
Published: (2016)

Dysregulated peripheral proteome reveals NASH-specific signatures identifying patient subgroups with distinct liver biology
by: Natalie Stiglund, et al.
Published: (2023-06-01)

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
by: Wei-Qiang Leow, et al.
Published: (2020-08-01)

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology
by: Anita M. van den Hoek, et al.
Published: (2020-09-01)

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
by: Elizabeth Clearfield, et al.
Published: (2021-05-01)

Proteomics and Metabolomics for Cystic Fibrosis Research
by: Nara Liessi, et al.
Published: (2020-07-01)

Ultra-high-field MR-spectroscopy in NAFLD: novel mechanistic and diagnostic insights of energy metabolism in NASH and advanced fibrosis
by: Traussnigg, S, et al.
Published: (2017)

Learning to Play Nash.
by: Foster, D, et al.
Published: (2000)

NAShI AVTORY
by: - -
Published: (2016-12-01)